UCSFi002-A-1

General

Cell Line

hPSCreg name UCSFi002-A-1
Cite as:
UCSFi002-A-1
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines No similar lines found.
Last update 22nd October 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Universitätsklinikum Bonn (UKB)
Owner Institute of Physiology I (PHYSI)
Distributors
Derivation country Germany

External Databases

BioSamples SAMEA116132044

General Information

* Is the cell line readily obtainable for third parties?
No
Subclone of

Donor Information

General Donor Information

Sex female
Ethnicity white

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Stage
TERMINAL
Genetic variants
BAG3
Heterozygous
VCV000005981.61
NM_004281.4
PMID: 19085932
SEVERE CARDIOMYOPATHY. ALSO GIANT AXON NEUROPATHY ASSOCIATED WITH THIS MUTATION
Family history NO
Is the medical history available upon request? NO
Is clinical information available? NO

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA116084038

Ethics

Also have a look at the ethics information for the parental line UCSFi002-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

The source cell information can be found in the parental cell line UCSFi002-A.
Passage number reprogrammed p8

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR

Vector free reprogramming

Other

Derived under xeno-free conditions
Unknown
Derived under GMP?
Unknown
Available as clinical grade?
Unknown

Culture Conditions

Medium Other medium:
Base medium: StemMACS iPS Brew XF Medium
Main protein source:
Serum concentration: %
Supplements
StemMACS iPS Brew XF 50x Supplement 10ml %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
TRA 1-60
Yes
SOX2
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro directed differentiation
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX
Passage number: p8
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)

Genetic Modification

Genetic modifications not related to a disease
Isogenic modification
10q26.11
Heterozygous
The mutation BAG3:c.626C>T (p.Pro209Leu) was repaired by introducing a point mutation (leucine to proline at position 209).
Repaired